Eagle Pharmaceuticals (EGRX) Tops Q4 EPS by 66c, Sales Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results
March 1, 2017 6:50 AM EST-- Bendeka® market share grew to 92% --
-- Bendeka reached $500 million in cumulative sales in Q1 2017, triggering $25 million milestone --
-- 2016 Revenue grew 186% to $189.5 million --
-- Q4 2016 income before tax benefit grew to $28.3 million, including $15.6 million of accelerated and non-recurring expenses
-- Q4 2016 EPS grew to $3.75 per basic and $3.52 per diluted share --
-- Full Year 2016 income before tax benefit grew to $53.4 million --
-- Full Year 2016 EPS grew to $5.24 per... More
